Mark Cuban tries to shake up biosimilar pricing with a version of J&J’s Stelara
In its latest bid to shake up the prescription drug market, the Mark Cuban Cost Plus Drug Company…
Britain’s plan to raise NHS drug prices won’t bring back Lilly’s investment – POLITICO
But for the U.S. pharmaceutical company — which shelved its planned facility meant to support early-stage life sciences…
US trade envoy Jamieson Greer to visit London in late November – POLITICO
Ministers agreed last week to a two-week extension to the deadline by which pharma firms must tell the…
Trump tariff threats punch holes in UK trade deal – POLITICO
Britain’s auto industry also only exports a small amount of Heavy Goods Vehicles to the U.S., but “we’re…
UK trade secretary takes dig at pharma sector amid crunch price talks – POLITICO
The prime minister’s business adviser, Varun Chandra, flew to Washington this week to discuss tariffs. In parallel, the…
Let the rulemaking begin: Why direct-to-consumer drug ads deserve a closer look
Call it death by disclosure. After nearly 30 years in which prescription drug ads have become a fixture…
Americans must stop subsidizing the price of drugs in other countries
President Trump is right that Americans often pay too much for prescription drugs, and that other countries aren’t…
New drug prices for rare diseases are increasing sharply
In This Story Drugs being explicitly developed to treat rare diseases are getting more expensive. How Trump’s tariffs…
Big Pharma is using tariffs to hold Europe to ransom – POLITICO
What we need is to work across Europe to build world-class, publicly controlled medical research capacity. Then, rather…
2025 Begins With 112 Drugs Waiting for Approval in Europe
As of December 31, 2024, a total of 112 drugs remained under evaluation by the European Medicines Agency…